Belatacept for the prevention of organ rejection in kidney transplantation
For information belatacept was considered within the MTA for Kidney transplantation (adults) - immunosuppressive therapy (ID456), rather than being appraised as a separate STA. This MTA has now published as TA481
 
Status Discontinued
Decision Selected
Process STA pre-2018
Referral date 01 July 2009
Topic area
  • Urogenital

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: Paul Cooney
Executive Lead: Peter Littlejohns
Project manager: Kate Moore
Technical Lead: Joao Vieira

Timeline

Key events during the development of the guidance:

Date Update
26 February 2016 Discontinued. For information belatacept was considered within the MTA for Kidney transplantation (adults) - immunosuppressive therapy (ID456), rather than being appraised as a separate STA. This MTA has now published as TA481

For further information on our processes and methods, please see our CHTE processes and methods manual